Skip to main content
OXFORD BIODYNAMICS PLC logo

OXFORD BIODYNAMICS PLC — Investor Relations & Filings

Ticker · OBD ISIN · GB00BD5H8572 LEI · 2138005Y1TK258O5U928 IL Professional, scientific and technical activities
Open in API
Filings indexed 416 across all filing types
Latest filing 2025-07-01 Major Shareholding Noti…
Country GB United Kingdom
Listing IL OBD

About OXFORD BIODYNAMICS PLC

https://www.oxfordbiodynamics.com/

Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests. The company's proprietary EpiSwitch® platform utilizes 3D genomics and epigenetic biomarkers to create diagnostic solutions for life-changing diseases, with a focus on oncology. Its portfolio of clinical tests includes the EpiSwitch® PSE, a blood test that assesses the likelihood of prostate cancer with high accuracy to help reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test designed to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. The platform enables the translation of 3D genome regulation into clinical applications for precision medicine at scale.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 2724P' and contains the standard formatting and disclosure requirements for notifications made via the London Stock Exchange's Regulatory News Service (RNS). The content itself is a 'TR-1: Standard form for notification of major holdings', which details changes in share ownership thresholds by a shareholder (Spreadex LTD). This type of filing, reporting changes in significant shareholdings, maps directly to the 'Major Shareholding Notification' definition. Code mapping: Major Shareholding Notification corresponds to 'MRQ'. Although it is an RNS filing, 'MRQ' is a more specific classification than the general 'RNS' fallback.
2025-07-01 English
Interim Results
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM RESULTS FOR THE SIX-MONTH PERIOD ENDED 31 MARCH 2025' and contains detailed financial highlights, operational updates, and an Executive Chairman's review. It provides substantive financial data (revenue, operating loss, cash position) for the specified interim period. It is not a mere announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report. H1 2025
2025-06-30 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled as an 'RNS Number' notification from 'Oxford BioDynamics PLC' dated '27 June 2025'. The form title is 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, specifically when a shareholder crosses or reaches a notification threshold. This directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the classification over the general regulatory filing fallback.
2025-06-27 English
OBD’s Oxford Lab accredited by UKAS
Regulatory Filings Classification · 100% confidence The document is a press release issued via the RNS (Regulatory News Service) platform. It announces a specific operational milestone for Oxford BioDynamics PLC: the UKAS accreditation of its Oxford laboratory and the validation of its EpiSwitch CiRT test. As this is a general corporate announcement regarding operational updates and does not fit into specific categories like financial reports, M&A, or director dealings, it falls under the 'Regulatory Filings' (RNS) category.
2025-05-09 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from Oxford BioDynamics PLC regarding a 'PDMR Dealing'. It details a share purchase by a Non-Executive Director (Peter Presland) and includes the mandatory disclosure table required under the UK Market Abuse Regulation for transactions by persons discharging managerial responsibilities. This fits the definition of a Director's Dealing (DIRS).
2025-04-10 English
PDMR Dealing
Director's Dealing Classification · 100% confidence The document is an official notification of a share transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically the Chief Financial Officer of Oxford BioDynamics PLC. It explicitly follows the UK Market Abuse Regulation (MAR) disclosure requirements for director dealings. This aligns perfectly with the definition for 'Director's Dealing' (DIRS).
2025-04-02 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.